Ralf Regenthal

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5885317/publications.pdf

Version: 2024-02-01

61 papers	2,266 citations	279798 23 h-index	223800 46 g-index
76 all docs	76 docs citations	76 times ranked	3548 citing authors

#	Article	IF	Citations
1	Atomoxetine Modulates Right Inferior Frontal Activation During Inhibitory Control: A Pharmacological Functional Magnetic Resonance Imaging Study. Biological Psychiatry, 2009, 65, 550-555.	1.3	274
2	Drug levels: therapeutic and toxic serum/plasma concentrations of common drugs. Journal of Clinical Monitoring and Computing, 1999, 15, 529-544.	1.6	226
3	Effects of modafinil on working memory processes in humans. Psychopharmacology, 2004, 177, 161-169.	3.1	153
4	Targeting impulsivity in Parkinsonâ€™s disease using atomoxetine. Brain, 2014, 137, 1986-1997.	7.6	116
5	Selective serotonin reuptake inhibition modulates response inhibition in Parkinsonâ€™s disease. Brain, 2014, 137, 1145-1155.	7.6	113
6	Effects of modafinil and methylphenidate on visual attention capacity: a TVA-based study. Psychopharmacology, 2010, 210, 317-329.	3.1	101
7	Improving Response Inhibition in Parkinsonâ€™s Disease with Atomoxetine. Biological Psychiatry, 2015, 77, 740-748.	1.3	93
8	A positron emission tomography study of nigro-striatal dopaminergic mechanisms underlying attention: implications for ADHD and its treatment. Brain, 2013, 136, 3252-3270.	7.6	90
9	Serotonergic Modulation of Intrinsic Functional Connectivity. Current Biology, 2014, 24, 2314-2318.	3.9	82
10	Atomoxetine restores the response inhibition network in Parkinsonâ€™s disease. Brain, 2016, 139, 2235-2248.	7.6	76
11	Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans. Neuropsychopharmacology, 2018, 43, 2645-2651.	5.4	72
12	Improving response inhibition systems in frontotemporal dementia with citalopram. Brain, 2015, 138, 1961-1975.	7.6	71
13	Predicting beneficial effects of atomoxetine and citalopram on response inhibition in <scp>P</scp>arkinson's disease with clinical and neuroimaging measures. Human Brain Mapping, 2016, 37, 1026-1037.	3.6	60
14	Changes in purinergic signaling after cerebral injury â€“ involvement of glutamatergic mechanisms?. International Journal of Developmental Neuroscience, 2006, 24, 123-132.	1.6	59
15	Altered serotonin transporter availability in patients with multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 827-835.	6.4	56
16	Carbonyl stress and NMDA receptor activation contribute to methylglyoxal neurotoxicity. Free Radical Biology and Medicine, 2006, 40, 779-790.	2.9	53
17	The serotonin transporter availability in untreated early-onset and late-onset patients with obsessiveâ€“compulsive disorder. International Journal of Neuropsychopharmacology, 2011, 14, 606-617.	2.1	53
18	Locus coeruleus integrity and the effect of atomoxetine on response inhibition in Parkinsonâ€™s disease. Brain, 2021, 144, 2513-2526.	7.6	53

#	Article	IF	Citations
19	The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. Psychopharmacology, 2009, 207, 35-45.	3.1	52
20	Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. Clinical Pharmacology and Therapeutics, 2018, 104, 317-325.	4.7	46
21	Dose-dependent emetic effects of the Amaryllidaceous alkaloid lycorine in beagle dogs. Toxicon, 2011, 57, 117-124.	1.6	38
22	Depression-like deficits in rats improved by subchronic modafinil. Psychopharmacology, 2009, 204, 627-639.	3.1	33
23	P2 receptors are involved in the mediation of motivation-related behavior. Purinergic Signalling, 2004, 1, 21-29.	2.2	26
24	In vivo assessment of antiemetic drugs and mechanism of lycorine-induced nausea and emesis. Archives of Toxicology, 2011, 85, 1565-1573.	4.2	23
25	Metabolic studies of the Amaryllidaceous alkaloids galantamine and lycorine based on electrochemical simulation in addition to in vivo and in vitro models. Analytica Chimica Acta, 2012, 756, 60-72.	5.4	22
26	Central serotonin transporter availability in highly obese individuals compared with non-obese controls: A [11C] DASB positron emission tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 1096-1104.	6.4	22
27	Anticonvulsant Profile of Flunarizine and Relation to Na+Channel Blocking Effects. Basic and Clinical Pharmacology and Toxicology, 2004, 94, 79-88.	2.5	21
28	Noradrenergic deficits contribute to apathy in Parkinsonâ€™s disease through the precision of expected outcomes. PLoS Computational Biology, 2022, 18, e1010079.	3.2	19
29	In vitro tolerance to inhibition by ethanol of N-methyl-d-aspartate-induced depolarization in locus coeruleus neurons of behaviorally ethanol-tolerant rats. Neurochemistry International, 2001, 39, 51-58.	3.8	17
30	Appropriate antibiotic prescribing among final-year medical students in Europe. International Journal of Antimicrobial Agents, 2019, 54, 375-379.	2.5	14
31	Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies. International Journal of Clinical Pharmacology and Therapeutics, 2020, 58, 426-438.	0.6	14
32	Plasma kinetics of procarbazine and azo-procarbazine in humans. Anti-Cancer Drugs, 2006, 17, 75-80.	1.4	13
33	The effect of serum BDNF levels on central serotonin transporter availability in obese versus non-obese adults: A [11C]DASB positron emission tomography study. Neuropharmacology, 2016, 110, 530-536.	4.1	13
34	Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation. Drug Design, Development and Therapy, 2018, Volume 12, 3653-3664.	4.3	13
35	D2 dopamine receptor occupancy, risperidone plasma level and extrapyramidal motor symptoms in previously drug-free schizophrenic patients. International Journal of Clinical Pharmacology and Therapeutics, 2005, 43, 370-378.	0.6	13
36	Oneâ€week escitalopram intake alters the excitationâ€“inhibition balance in the healthy female brain. Human Brain Mapping, 2022, 43, 1868-1881.	3.6	11

#	Article	IF	Citations
37	Poisoning with tilidine and naloxone: toxicokinetic and clinical observations. Human and Experimental Toxicology, 1998, 17, 593-597.	2.2	8
38	Prefrontal Cortex Activation and Stopping Performance Underlie the Beneficial Effects of Atomoxetine on Response Inhibition in Healthy Volunteers and Those With Cocaine Use Disorder. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2022, 7, 1116-1126.	1.5	6
39	A Novel Cardenolide Photoaffinity Label for the Na/K-ATPase. Tetrahedron, 2000, 56, 9625-9632.	1.9	4
40	Evaluation of REMEDi HS in the Diagnosis of Dimethoate Poisoning. Therapeutic Drug Monitoring, 2002, 24, 297-301.	2.0	3
41	In-vivo serotonin transporter availability and somatization in healthy subjects. Personality and Individual Differences, 2016, 94, 354-359.	2.9	3
42	Modulation of premotor cortex response to sequence motor learning during escitalopram intake. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1449-1462.	4.3	3
43	Validation of an LC-MS/MS Method to Quantify the New TRPC6 Inhibitor SH045 (Larixyl) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 Pharmaceuticals, 2021, 14, 259.	3.8	3
44	A single dose of escitalopram blunts the neural response in the thalamus and caudate during monetary loss. Journal of Psychiatry and Neuroscience, 2021, 46, E319-E327.	2.4	3
45	Fulminant thrombotic thrombocytopenic purpura (TTP): association with amphetamine consumption?. Annals of Hematology, 2015, 94, 337-338.	1.8	2
46	Mapping the effects of atomoxetine during response inhibition across cortical territories and the locus coeruleus. Psychopharmacology, 2022, 239, 365-376.	3.1	2
47	Characterization of Drug Release from Mesoporous SiO2-Based Membranes with Variable Pore Structure and Geometry. Pharmaceutics, 2022, 14, 1184.	4.5	2
48	Presence and function of Î²-adrenergic receptors in primary equine bronchial epithelia cells. Pulmonary Pharmacology and Therapeutics, 2020, 61, 101897.	2.6	1
49	Expression of muscarinic acetylcholine receptors in turkey cardiac chambers. Research in Veterinary Science, 2021, 136, 602-608.	1.9	1
50	Decreased thalamo-cortico connectivity during an implicit sequence motor learning task and 7Âdays escitalopram intake. Scientific Reports, 2021, 11, 15060.	3.3	1
51	Nutraceuticals in mental diseases â€" Bridging the gap between traditional use and modern pharmacology. Current Opinion in Pharmacology, 2021, 61, 62-68.	3.5	1
52	Impact of medication on blood transcriptome reveals off-target regulations of beta-blockers. PLoS ONE, 2022, 17, e0266897.	2.5	1
53	P.6.d.014 Investigating â€˜waiting impulsivityâ€™ in cocaine addiction: are the effects of atomoxetine mediated by genotype?. European Neuropsychopharmacology, 2015, 25, S619.	0.7	0
54	Search for an animal model to investigate selective pulmonary vasodilation. Laboratory Animals, 2017, 51, 376-387.	1.0	0

#	Article	IF	Citations
55	The Rho kinase (ROCK) inhibitor Y-27632 reduces the Î²2-adrenoceptor density but enhance cAMP formation in primary equine bronchial epithelial cells. European Journal of Pharmacology, 2021, 907, 174323.	3.5	0
56	Effects of oral methylphenidate on [18F]fallypride binding in healthy volunteers and adults with attention-deficit hyperactivity disorder (ADHD). Pharmacopsychiatry, 2009, 42, .	3.3	0
57	Plasma level-dependent effects of methylphenidate and modafinil on processing speed and short term memory capacity parameters of the theory of visual attention (TVA) task. Pharmacopsychiatry, 2009, 42, .	3.3	0
58	Aripiprazole and sulpiride have differenzial effects on working memory performance and brain activity in patients with schizophrenia and healthy controls. Pharmacopsychiatry, 2009, 42, .	3.3	0
59	Sulpiride modulates striatal BOLD signal during the manipulation of information in working memory. Pharmacopsychiatry, 2009, 42, .	3.3	0
60	Potential Drug Interactions Forgotten. Deutsches Ärzteblatt International, 2019, 116, 71-72.	0.9	0
61	A Pharmacokinetic and Metabolism Study of the TRPC6 Inhibitor SH045 in Mice by LC-MS/MS. International Journal of Molecular Sciences, 2022, 23, 3635.	4.1	0